• LAST PRICE
    0.9300
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.8900/ 19
  • Ask / Lots
    0.9500/ 9
  • Open / Previous Close
    0.9000 / 0.9300
  • Day Range
    Low 0.8901
    High 0.9555
  • 52 Week Range
    Low 0.4200
    High 1.7700
  • Volume
    22,826
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.925349
TimeVolumeCMMB
09:57 ET82340.9
10:24 ET1000.92
10:30 ET2000.9
10:32 ET1000.92
10:51 ET9550.919899
12:43 ET3980.896553
12:45 ET5000.8901
12:54 ET1070.8923
12:57 ET18150.918813
12:59 ET10000.9199
01:01 ET5000.910499
01:21 ET3000.905
02:18 ET11670.9478
02:45 ET10000.91
02:47 ET1000.9555
03:09 ET1000.91
03:34 ET3000.910101
03:36 ET2000.91
03:43 ET2000.910101
03:45 ET3000.91
03:57 ET11000.93
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCMMB
Chemomab Therapeutics Ltd
13.2M
0.0x
---
United StatesXTLB
X T L Biopharmaceuticals Ltd
13.1M
-6.8x
---
United StatesGLTO
Galecto Inc
13.5M
-0.4x
---
United StatesCUBT
Curative Biotechnology Inc
13.5M
-1.4x
---
United StatesINTI
Inhibitor Therapeutics Inc
13.6M
-4.3x
---
United StatesKTRA
Kintara Therapeutics Inc
13.7M
-0.1x
---
As of 2024-06-22

Company Information

Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Contact Information

Headquarters
Kiryat Atidim, Building 7TEL AVIV-YAFO, Israel 6158002
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Nissim Darvish
Chief Executive Officer, Director
Adi Mor
Chief Financial Officer
Sigal Fattal
Chief Medical Officer, Vice President - Drug Development
Matthew Frankel
Independent Director
Neil Cohen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$13.2M
Revenue (TTM)
$0.00
Shares Outstanding
14.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.50
EPS
$-26.80
Book Value
$23.93
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.